Sansure Biotech, Inc. (688289) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sansure Biotech, Inc.

Why is Sansure Biotech, Inc. ?

Poor Management Efficiency with a low ROCE of 87.81%

The company has been able to generate a Return on Capital Employed (avg) of 87.81% signifying low profitability per unit of total capital (equity and debt)

The company is Net-Debt Free

Poor long term growth as Net Sales has grown by an annual rate of -16.49% and Operating profit at -49.15% over the last 5 years
The company is Net-Debt Free
The company has been able to generate a Return on Equity (avg) of 18.63% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of -16.49% and Operating profit at -49.15% over the last 5 years

The company has declared negative results for the last 4 consecutive quarters

ROCE(HY) Lowest at 1.88%
INTEREST COVERAGE RATIO(Q) Lowest at 753.05
CASH AND EQV(HY) Lowest at CNY 7,743.59 MM

Underperformed the market in the last 1 year

Even though the market (China Shanghai Composite) has generated returns of 3.40% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -18.17% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sansure Biotech, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sansure Biotech, Inc.

-18.08%

-0.27

36.48%

China Shanghai Composite

3.23%

0.23

14.72%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-16.49%

EBIT Growth (5y)

-49.15%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.50

Sales to Capital Employed (avg)

0.18

Tax Ratio

6.85%

Dividend Payout Ratio

151.11%

Pledged Shares

Institutional Holding

ROCE (avg)

41.67%

ROE (avg)

18.63%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

113

Industry P/E

Price to Book Value

1.14

EV to EBIT

68.30

EV to EBITDA

21.26

EV to Capital Employed

1.23

EV to Sales

3.40

PEG Ratio

Dividend Yield

3.76%

ROCE (Latest)

1.80%

ROE (Latest)

1.01%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 314.93 MM

-33What is not working for the Company

ROCE(HY)

Lowest at 1.88%

INTEREST COVERAGE RATIO(Q)

Lowest at 753.05

CASH AND EQV(HY)

Lowest at CNY 7,743.59 MM

DEBT-EQUITY RATIO (HY)

Highest at -32.69 %

INTEREST(Q)

Highest at CNY 7.24 MM

OPERATING PROFIT(Q)

Lowest at CNY 54.49 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 13.73 %

PRE-TAX PROFIT(Q)

Lowest at CNY -27.21 MM

NET PROFIT(Q)

Lowest at CNY -21.94 MM

Here's what is working for Sansure Biotech, Inc.

Operating Cash Flow

Highest at CNY 314.93 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Here's what is not working for Sansure Biotech, Inc.

Pre-Tax Profit

At CNY -27.21 MM has Fallen at -173.07%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -21.94 MM has Fallen at -173.57%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Interest Coverage Ratio

Lowest at 753.05

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest

Highest at CNY 7.24 MM

in the last five periods and Increased by 9.75% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Profit

Lowest at CNY 54.49 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 13.73 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY -27.21 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY -21.94 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Cash and Eqv

Lowest at CNY 7,743.59 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -32.69 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio